Alto Neuroscience, Inc. (NYSE:ANRO) Receives Average Recommendation of “Moderate Buy” from Analysts

Alto Neuroscience, Inc. (NYSE:ANRO) has been given an average recommendation of “Moderate Buy” by the eight research firms that are covering the firm, MarketBeat Ratings reports. Three investment analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $20.00.

ANRO has been the subject of a number of analyst reports. Robert W. Baird lowered their price target on shares of Alto Neuroscience from $32.00 to $10.00 and set an “outperform” rating for the company in a report on Wednesday, October 23rd. Wedbush lowered Alto Neuroscience from an “outperform” rating to a “neutral” rating and lowered their price objective for the company from $29.00 to $4.00 in a research note on Wednesday, October 23rd. Stifel Nicolaus cut their target price on Alto Neuroscience from $32.00 to $10.00 and set a “buy” rating on the stock in a research report on Wednesday, November 13th. RODMAN&RENSHAW downgraded Alto Neuroscience from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 23rd. Finally, Rodman & Renshaw cut shares of Alto Neuroscience from a “buy” rating to a “neutral” rating in a research report on Wednesday, October 23rd.

Alto Neuroscience Trading Down 7.2 %

NYSE:ANRO opened at $3.67 on Friday. Alto Neuroscience has a 1 year low of $3.56 and a 1 year high of $19.66. The stock’s 50 day simple moving average is $4.22 and its two-hundred day simple moving average is $7.88. The company has a quick ratio of 13.09, a current ratio of 13.10 and a debt-to-equity ratio of 0.05.

Alto Neuroscience (NYSE:ANRO) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.62) earnings per share for the quarter, topping the consensus estimate of ($0.67) by $0.05. As a group, analysts anticipate that Alto Neuroscience will post -2.54 earnings per share for the current year.

Institutional Trading of Alto Neuroscience

Several institutional investors and hedge funds have recently made changes to their positions in the business. BNP Paribas Financial Markets grew its holdings in shares of Alto Neuroscience by 619.2% in the third quarter. BNP Paribas Financial Markets now owns 4,315 shares of the company’s stock worth $49,000 after purchasing an additional 3,715 shares during the last quarter. Jane Street Group LLC purchased a new position in shares of Alto Neuroscience during the third quarter worth approximately $124,000. MetLife Investment Management LLC bought a new stake in shares of Alto Neuroscience during the third quarter valued at approximately $146,000. JPMorgan Chase & Co. boosted its holdings in shares of Alto Neuroscience by 543.4% in the third quarter. JPMorgan Chase & Co. now owns 24,315 shares of the company’s stock valued at $278,000 after purchasing an additional 20,536 shares during the period. Finally, Rhumbline Advisers grew its stake in Alto Neuroscience by 24.4% in the fourth quarter. Rhumbline Advisers now owns 25,556 shares of the company’s stock worth $108,000 after purchasing an additional 5,008 shares in the last quarter.

About Alto Neuroscience

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.